Skip to main content

Beyond Meat, 5 Top Stock Gainers for Tuesday

Beyond Meat,, Zentalis Pharmaceuticals, Arcutis Biotherapeutics, and Angiodynamics are five of Tuesday's top gainers.
  • Author:
  • Publish date:

Stocks finished lower Tuesday as investors were discouraged by the lack of progress on a fiscal stimulus package and focused Tuesday evening's debate between President Donald Trump and Democratic presidential candidate Joe Biden.

Here are some of the top gainers Tuesday:

1. Beyond Meat | Percentage Increase Over 9%

Beyond Meat  (BYND) - Get Free Report shares surged after the plant-based-food company said it reached an agreement with Walmart  (WMT) - Get Free Report to expand its distribution through the world's largest retailer. Walmart will triple the availability of the Beyond Meat burger.

2. | Percentage Increase Over 11%  (SOHU) - Get Free Report climbed after the Beijing internet company said that its Sogou  (SOGO) - Get Free Report subsidiary is being acquired by Chinese conglomerate Tencent Holdings  (TCEHY)  for $1.18 billion.

3. Zentalis Pharmaceuticals | Percentage Increase Over 14%

Zentalis Pharmaceuticals  (ZNTL) - Get Free Report advanced after Cantor Fitzgerald analyst Eliana Merle initiated coverage of the company with an overweight rating and $44 price target. She sees "long-term underappreciated value potential" from the oncology portfolio.

4. Arcutis Biotherapeutics | Percentage Increase 16%

Arcutis Biotherapeutics  (ARQT) - Get Free Report climbed after the company reported positive top-line data from its Phase 2 clinical trial evaluating ARQ-154, a topical roflumilast foam, as a potential treatment for the skin condition seborrheic dermatitis. Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile, the company said.

5. Angiodynamics | Percentage Increase Over 19%

Angiodynamics  (ANGO) - Get Free Report rose after the medical-device maker beat Wall Street's second-quarter-earnings expectations. The company reported earnings of 2 cents a share, beating the Zacks consensus estimate of a loss of 6 cents a share. Revenue totaled $70.2 million, beating the Zacks estimate by 7%